Peripheral BDNF: a candidate biomarker of healthy neural activity during learning is disrupted in schizophrenia

A. J. Skilleter1,2,3, C. S. Weickert1,2,3, A. Vercammen1,2,3†, R. Lenroot1,2,3 and T. W. Weickert1,2,3*

1 School of Psychiatry, University of New South Wales, Kensington, NSW, Australia
2 Neuroscience Research Australia, Randwick, NSW, Australia
3 Schizophrenia Research Institute, Darlinghurst, NSW, Australia

Background. Brain-derived neurotrophic factor (BDNF) is an important regulator of synaptogenesis and synaptic plasticity underlying learning. However, a relationship between circulating BDNF levels and brain activity during learning has not been demonstrated in humans. Reduced brain BDNF levels are found in schizophrenia and functional neuroimaging studies of probabilistic association learning in schizophrenia have demonstrated reduced activity in a neural network that includes the prefrontal and parietal cortices and the caudate nucleus. We predicted that brain activity would correlate positively with peripheral BDNF levels during probabilistic association learning in healthy adults and that this relationship would be altered in schizophrenia.

Method. Twenty-five healthy adults and 17 people with schizophrenia or schizo-affective disorder performed a probabilistic association learning test during functional magnetic resonance imaging (fMRI). Plasma BDNF levels were measured by enzyme-linked immunosorbent assay (ELISA).

Results. We found a positive correlation between circulating plasma BDNF levels and brain activity in the parietal cortex in healthy adults. There was no relationship between plasma BDNF levels and task-related activity in the prefrontal, parietal or caudate regions in schizophrenia. A direct comparison of these relationships between groups revealed a significant diagnostic difference.

Conclusions. This is the first study to show a relationship between peripheral BDNF levels and cortical activity during learning, suggesting that plasma BDNF levels may reflect learning-related brain activity in healthy humans. The lack of relationship between plasma BDNF and task-related brain activity in patients suggests that circulating blood BDNF may not be indicative of learning-dependent brain activity in schizophrenia.

Received 12 January 2014; Revised 16 July 2014; Accepted 16 July 2014; First published online 27 August 2014

Key words: BDNF, biomarker, brain-derived neurotrophic factor, functional MRI, plasma, probabilistic association learning, schizophrenia.
learning has not been demonstrated and the extent to which lower circulating BDNF may be indicative of the neural correlates of cognitive impairment in schizophrenia has not been shown. Low peripheral BDNF is reported in first-episode psychosis (Buckley et al. 2007) and is associated with cognitive impairment in clinically ill people with schizophrenia (Zhang et al. 2012). Peripheral BDNF levels are also significantly decreased in people with mild cognitive impairment (Yu et al. 2008). Thus, peripheral BDNF levels may be useful as a biomarker in health and disease. However, to more fully interpret what any change in a potential biomarker may mean for brain function, a relationship between peripheral BDNF and brain activity should be established in the healthy and diseased states.

One reason that general predictions about blood-brain relationships in schizophrenia are difficult to make is that studies of peripheral BDNF levels in schizophrenia have reported inconsistent results. Although the majority of studies report decreased circulating BDNF levels (Pirildar et al. 2004; Tan et al. 2005; Grillo et al. 2007; Rizos et al. 2008), some find increased levels (Gama et al. 2007; Reis et al. 2008), and one study reports no significant difference in plasma BDNF levels in people with schizophrenia compared to healthy controls (Lee & Kim, 2009). A recent meta-analysis supports an overall reduction in peripheral BDNF levels in schizophrenia (Green et al. 2011). However, the extent to which alterations in blood BDNF levels relate to abnormal learning-related brain activity in schizophrenia, as compared to healthy individuals, remains to be demonstrated.

Healthy cortical neurons innervate and supply BDNF to several brain regions, including the striatum (Alexander et al. 1986; Altar & DiStefano, 1998). As striatal neurons are trophically dependent on BDNF supplied through anterograde transport from the frontal cortex (Hofer et al. 1990; Altar et al. 1997; Rauskolb et al. 2010; Dieni et al. 2012), higher levels of BDNF would be expected to relate to stronger frontal–striatal activity in a healthy brain, and a reduction of prefrontal cortical BDNF, as found in schizophrenia (Weickert et al. 2003; Hashimoto et al. 2005), would be expected to negatively impact striatal function in schizophrenia.

There is abundant evidence from neuropsychological and neuroimaging studies demonstrating significant learning impairments and frontal–striatal dysfunction in schizophrenia (Pantelis et al. 1997; Meyer-Lindenberg et al. 2002; Murray et al. 2008; Howes et al. 2009; Weickert et al. 2010; Morris et al. 2012). Probabilistic association learning (requiring gradual learning of probabilistic-based cue–outcome associations) elicits frontal–parietal–striatal activity in healthy people (Poldrack et al. 1999; Fera et al. 2005) and is related to reduced activity in a neural network that includes the dorsolateral prefrontal cortex (DLPFC), parietal cortex and caudate nucleus in schizophrenia (Weickert et al. 2009). Probabilistic association learning is impaired in people with schizophrenia (Weickert et al. 2002; Foerde et al. 2008; Horan et al. 2008), the offspring of people with schizophrenia who are at high risk of developing schizophrenia (Wagshal et al. 2012, 2013) and in unaffected siblings of people with schizophrenia (Weickert et al. 2010; Wagshal et al. 2014), with deficits in overall performance and learning rate.

In the present study, we sought to define the relationship between peripheral BDNF levels and the neural processes underlying probabilistic association learning in healthy people and people with schizophrenia. First, we confirmed the reduced brain activation in people with schizophrenia versus healthy controls during a probabilistic association learning test using functional magnetic resonance imaging (fMRI). Second, we tested the extent to which plasma BDNF levels are related to brain activity in healthy people during probabilistic association learning. Third, we determined whether a similar relationship was also present in schizophrenia. We predicted a positive relationship between plasma BDNF levels and brain activity in a neural network consisting of prefrontal—parietal cortices and striatum, which has previously been shown to be relevant for probabilistic association learning in healthy adults. Based on the majority of work showing dysregulation of either BDNF levels or prefrontal cortex activity along with an increase in the truncated BDNF receptor (Weickert et al. 2003; Hashimoto et al. 2005; Wong et al. 2010, 2013; Ray et al. 2014), which is thought to block trophic effects in schizophrenia, we further predicted an abnormal relationship between plasma BDNF levels and brain activity in schizophrenia.

Method

Participants

Twenty-eight healthy adults without a personal or family history of mental illness and 20 chronically ill adults with a diagnosis of schizophrenia or schizo-affective disorder were recruited for participation in the study. All patients met the DSM-IV criteria for schizophrenia or schizo-affective disorder on the basis of the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID; First et al. 2002). All participants were screened for exclusion criteria, which included a concurrent DSM-IV Axis I diagnosis other than schizophrenia or schizo-affective disorder in patients, or any DSM-IV diagnosis in healthy adults,
and for all participants: history of uncontrolled diabetes or cardiovascular disease including hypertension, recent alcohol/substance abuse (within the past 5 years), head injury with loss of consciousness, epileptic seizures, structural brain abnormalities, developmental disorders, mental retardation and/or central nervous system (CNS) infection. Healthy adults having a first-degree relative with schizophrenia or schizoaffective disorder were also excluded. A four-subtest version of the Wechsler Adult Intelligence Scale, 3rd Edition (WAIS-III; Wechsler, 1997) and the Wechsler Test of Adult Reading (WTAR; Wechsler, 2001) were administered to all participants to obtain estimates of current IQ and premorbid IQ in schizophrenia. All people with schizophrenia were receiving antipsychotic medication (82% receiving second-generation antipsychotics) for at least 1 year prior to participation and 41% were receiving antidepressant medication. All participants had normal vision or their vision was corrected to normal with MRI-compatible lenses.

Demographic characteristics of each group are shown in Table 1. The mean daily dose of antipsychotic medication for each person with schizophrenia was converted to an approximate daily mean chlorpromazine (CPZ) milligram equivalents dose using standard guidelines (Leucht et al. 2003; Woods, 2003). Symptom severity in people with schizophrenia was assessed by a trained psychologist or psychometrician using the Positive and Negative Syndrome Scale (PANSS; Kay et al. 1987). All procedures were approved by the University of New South Wales and the South Eastern Sydney and Illawarra Area Health Service Human Research Ethic Committees. The procedure was explained and written informed consent was obtained from each participant before entry into the study.

**Circulating BDNF level assay**

Plasma samples from all participants were collected in 9-ml ethylenediaminetetraacetic acid (EDTA) tubes between 0900 and 1100 h on the day of the MRI scan, put on ice and stored at −80 °C until the day of assay. BDNF protein was measured in each plasma sample by an enzyme-linked immunosorbent assay (ELISA) kit (no. G7611, Promega Corporation, USA) according to standard protocol (see online Supplementary Material for details). All samples were assayed in duplicate in each plate over two different assay days (with up to four measurements for each participant).

**Probabilistic association learning Weather Prediction Task (WPT)**

Participants completed a probabilistic association learning WPT in the scanner, which alternates the experimental and perceptual-motor control tests as described in detail previously (Poldrack et al. 1999; Fera et al. 2005; Weickert et al. 2009) (see online Supplementary Material).

**Scanning procedure**

A 3-T Phillips Achieva MRI scanner with an eight-channel birdcage head coil at Neuroscience Research Australia, Randwick, Australia was used to acquire 162 whole-brain echo planar images: repetition time/echo time (TR/TE)=3000/30, 45 interleaved slices, thickness=3 mm, gap=0.3 mm, voxel size=2.14×2.14×3 mm, flip angle=90°, field of view (FOV)=240 mm. A T1-weighted high-resolution anatomical scan was obtained for each participant for registration purposes: TR/TE=5.3/2.4, 180 slices, thickness=1 mm, no gap, voxel size=1×1×1 mm, FOV=256 mm.

The experimental paradigm consisted of 16 blocks of 30 s each in which weather prediction blocks (six trials/block) alternated with the control task (six trials/block). There were 48 weather prediction and 48 perceptual-motor control trials in total, equating to eight blocks of each condition. One hundred and sixty-two scans were collected in a total scan time of 8.25 min. Stimuli for both tests were presented on an inverted computer screen that participants could see using a mirror mounted in the MRI head coil. Behavioral responses (left button press for ‘rain/two’ and right button press for ‘shine/not two’) were made with the right thumb and were recorded using a fiber-optic response box (Lumina Systems, Cedrus Corp., USA), which collected accuracy (number correct) and reaction time (ms) measures. All stimuli were displayed on the screen for 4.5 s with an intertrial interval of 0.5 s. The words ‘correct’ or ‘incorrect’ appeared immediately following a button press response as feedback to the participant during both the weather prediction and perceptual-motor control tests. Missed trials were not included in the scoring.

**fMRI processing**

Preprocessing was performed with SPM8 (Wellcome Trust Centre for Neuroimaging, UK), running under MATLAB version 2010b. Functional images were realigned to the first image in the sequence. Three dummy scans were obtained before each fMRI data acquisition to allow for equilibration of the MRI signal. Functional images were co-registered with the anatomical image. Images were smoothed with an 8-mm full-width at half-maximum (FWHM) Gaussian kernel. Movement parameters created during pre-processing were applied as a regressor covariate. Anatomical scans were also screened for structural abnormalities.
by a radiologist. All data sets were screened for artifacts, excessive movement (>3 mm along x, y or z axes), and unsuccessful normalization. We excluded three healthy controls and three people with schizophrenia due to excessive movement, leaving 25 controls and 17 people with schizophrenia whose data were entered into our analyses.

### Data analysis

*Group comparisons on demographics and BDNF*

Demographic variables and plasma BDNF levels of the schizophrenia and healthy control groups were compared using *t* tests and ANOVAs for continuous variables or *χ^2* tests for categorical variables. Although

| Table 1. Demographic summary of the schizophrenia and healthy control samples |
|--------------------------------------------------------------------------|
| **Schizophrenia (n=17)** | **Controls (n=25)** | df | *t* value/*χ^2* | *p* |
|-----------------------------------------------|------------------|----|----------------|-----|
| Age (years) 38.0 (9.2) | 29.2 (6.8) | 40 | 3.57 | 0.001 |
| Gender M/F 8/9 | 13/12 | 1 | 0.10 | 0.750 |
| Education years 14.4 (2.7) | 15.1 (2.0) | 40 | 0.99 | 0.330 |
| WAIS-III FSIQ 95.5 (11.9) | 107.8 (12.1) | 40 | 3.26 | 0.002 |
| WTAR 104.8 (4.9) | 110.2 (6.0) | 40 | 3.00 | 0.004 |
| Schizophrenia/schizo-affective disorder 8/9 | | | | |
| Age of illness onset (years) 25.2 (7.2) | | | | |
| Duration of illness (years) 12.9 (6.6) | | | | |
| CPZ equivalence dose (mg/day) 552.8 (416.3) | | | | |
| PANSS Positive 13.3 (5.1) | | | | |
| PANSS Negative 14.0 (4.9) | | | | |
| Antipsychotic medications | | | | |
| Amisulpride 2 | | | | |
| Clozapine+aripiprazole 1 | | | | |
| Clozapine+chlorpromazine 1 | | | | |
| Clozapine+haloperidol 1 | | | | |
| Clozapine+paliperidone 1 | | | | |
| Clozapine+risperidone 2 | | | | |
| Flupentixol 1 | | | | |
| Haloperidol 1 | | | | |
| Olanzapine 1 | | | | |
| Quetiapine 2 | | | | |
| Quetiapine+zuclopenthixol 1 | | | | |
| Ziprasidone 2 | | | | |
| Zuclopenthixol 1 | | | | |
| Antidepressant medications | | | | |
| Citalopram 1 | | | | |
| Escitalopram 1 | | | | |
| Escitalopram+lithium carbonate 1 | | | | |
| Fluoxetine 1 | | | | |
| Lithium 1 | | | | |
| Sertraline 1 | | | | |
| Venlafaxine 1 | | | | |
| Other medications | | | | |
| Albuterol 1 | | | | |
| Atorvastatin 2 | | | | |
| Benztropine 1 | | | | |
| Calcium carbonate 1 | | | | |
| Diazepam 1 | | | | |
| Metformin 2 | | | | |
| Metoprolol 1 | | | | |
| Pantoprazole 1 | | | | |
| Sodium valproate 3 | | | | |
| Telmisartan 1 | | | | |
| Thyroxine 1 | | | | |

M, Male; F, female; WAIS-III FSIQ, Wechsler Adult Intelligence Scale 3rd edition full-scale IQ estimate; WTAR, Wechsler Test of Adult Reading; CPZ, chlorpromazine; PANSS, Positive and Negative Syndrome Scale; df, degrees of freedom.

Means or numbers provided. Standard deviation in parentheses.
the groups differed significantly on age \((p=0.001)\), with controls significantly younger than people with schizophrenia (see Results), our main objective was to compare blood BDNF and blood oxygen level-dependent (BOLD) activity within diagnostic groups and not to test for a diagnostic difference between groups. Thus, we opted to retain the largest number of participants as possible rather than match on the basis of age. The degree of correlation among plasma BDNF levels, age, PANSS scores and CPZ equivalent dose was performed using Pearson’s product-moment correlations.

Statistica version 12 was used for statistical analyses of behavioral and clinical measures. The \(\alpha\) level for statistical significance was set at \(p<0.05\).

Probabilistic association learning analysis

The mean cumulative percentage correct after 48 trials was used as a measure of learning the cue–outcome associations. We also performed separate \(t\) tests at each trial block relative to chance (50% correct) in each group to test for significant improvement from chance levels.

fMRI analyses

A description of the whole-brain analysis is presented in the online Supplementary Material.

Region of interest (ROI) regression analysis of the relationship of BDNF on frontal–parietal–striatal activity

The novel analysis in this study was an ROI analysis in which the ROIs were chosen \(a\) \(p\)riori based on the frontal–parietal–striatal brain regions previously related to probabilistic association learning in healthy adults (Poldrack et al. 1999; Fera et al. 2005; Weickert et al. 2009). Bilateral DLPFC, parietal cortex and caudate nucleus ROIs were defined structurally according to the Anatomical Automatic Labeling atlas (Tzourio-Mazoyer et al. 2002), such that there were six ROIs in total and \(\beta\) weights were extracted from each ROI. Plasma BDNF levels were then correlated with the \(\beta\) weights from each ROI within each group and a family-wise error (FWE) rate correction for multiple comparisons was applied. Correlation strengths between groups were compared directly using a Fisher \(r\) to \(z\) transformation. Correlation of daily CPZ equivalent dose and \(\beta\) weights from each ROI were also performed in people with schizophrenia to determine the extent to which antipsychotics influence brain activation during learning.

Ethical considerations

All procedures contributing to this work complied with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.

Results

Demographic measures

The results of the demographic analyses are provided in Table 1. The groups did not differ significantly on the basis of gender distributions or education. There were expected significant group differences on WAIS-III IQ and WTAR scores, such that people with schizophrenia scored significantly lower than controls.

Probabilistic association learning and plasma BDNF levels

Plasma BDNF levels and probabilistic association learning performance of participants during the scan are presented in Table 2. Plasma BDNF levels were significantly increased in schizophrenia relative to controls. An ANOVA with sex and diagnostic status as grouping factors and BDNF levels as the dependent variable showed a main significant effect of diagnostic group \((F_{1,38}=6.01, p=0.02)\), such that controls had lower plasma BDNF levels than people with schizophrenia. There was no significant main effect of sex on plasma BDNF levels \((F_{1,38}=3.44, p=0.07)\). There was a significant interaction between sex and diagnostic group on plasma BDNF levels \((F_{1,38}=6.32, p=0.02)\).

Table 2. Mean plasma BDNF levels and percentage correct during probabilistic association learning in people with schizophrenia and healthy controls

|                      | Schizophrenia | Controls | \(t\) value | df | \(p\)  |
|----------------------|---------------|----------|-------------|----|-------|
| Plasma BDNF (ng/ml)  | 1.83 (1.49)   | 1.00 (0.75) | −2.39       | 40 | 0.02  |
| Probabilistic association learning percentage correct over 48 trials | 61.2 (9.0) | 65.4 (6.7) | 1.7 | 40 | 0.09  |
| Number of missed trials | 0.5 (0.8)  | 0.4 (0.8) | −0.2        | 40 | 0.83  |

BDNF, Brain-derived neurotrophic factor; df, degrees of freedom. Standard deviation in parentheses.
such that there was no significant difference in plasma BDNF levels on the basis of sex in the control group ($p=0.61$); however, there were significant differences in plasma BDNF levels on the basis of sex in the patient group, in which the female patients displayed significantly higher plasma BDNF levels than male patients ($p=0.007$) and both male ($p=0.003$) and female healthy controls ($p=0.001$).

The results of an unmatched $t$ test on the cumulative mean percentage correct after 48 trials of probabilistic association learning revealed a trend towards a significant group difference, such that controls tended to perform better than people with schizophrenia. Regarding performance relative to chance, controls performed significantly above chance levels from block 2 to block 8 ($p<0.001$) and people with schizophrenia performed significantly above chance levels from block 4 to block 8 ($p<0.01$). Both groups missed less than 1% of the total number of trials and there was no significant difference between groups with respect to the mean number of missed trials (see Table 2).

No strong, significant correlations were obtained between plasma BDNF levels and probabilistic association learning performance after 48 trials in controls ($r=0.19$, $p=0.36$) or in people with schizophrenia ($r=0.17$, $p=0.53$). There was a non-significant positive correlation between plasma BDNF level and daily CPZ equivalent dose in people with schizophrenia ($r=0.36$, $p=0.16$).

**fMRI analysis results**

Healthy controls showed increased activation in frontal–striatal and parietal regions during probabilistic association learning (Fig. 1a and online Supplementary Table S2). People with schizophrenia also showed activity in similar frontal–striatal and parietal regions during probabilistic association learning, although this seemed to be less robust (Fig. 1b and online Supplementary Table S2).

Direct comparisons between groups revealed that the medial frontal gyri, right precuneus and left caudate were more active in healthy controls than people with schizophrenia (Fig. 2a), replicating our previous work (Weickert et al. 2009). A larger network encompassing the temporal lobes, inferior frontal gyrus, cingulate gyrus and postcentral gyrus was found to show greater activity in people with schizophrenia compared to healthy controls (Fig. 2b), also replicating our previous findings.

**ROI analyses: correlations with plasma BDNF levels**

Plasma BDNF levels showed strong, significant, positive correlations with brain activation in the bilateral caudate and right parietal cortex in healthy adults during probabilistic association learning (Table 3 and Fig. 3). After applying FWE rate corrections for multiple comparisons using Hochberg’s step-up procedure, only the correlation between plasma BDNF levels and activity in the right parietal cortex remained significant. There were no strong, significant correlations between plasma BDNF levels and activation in any of the six ROIs in people with schizophrenia (Table 3). The results of the Fisher $r$ to $z$ transformation revealed that the correlation between the right parietal cortex and peripheral BDNF levels was significantly different between healthy controls and people with schizophrenia.
(Table 4) and the correlation of BDNF with the left caudate nucleus showed a trend towards a significant difference between groups ($p=0.06$).

**Correlations of BDNF levels and brain activity with other variables**

There were no strong, significant correlations among plasma BDNF levels and the following variables in patients and/or controls: brain activity in the ROIs for the motor control task, age and symptom severity (in patients) (see online Supplementary Tables S3–S5). There were also no strong, significant correlations among brain activity in the ROIs examined and the following factors in patients: daily CPZ equivalent dose and symptom severity (see online Supplementary Tables S6–S7).

**Discussion**

This is the first study to report a significant positive relationship between plasma BDNF levels and brain activity in the right parietal cortex, which receives prominent afferent input from the frontal cortex, during probabilistic association learning in healthy adults. Additionally, supporting our prediction of an altered relationship between plasma BDNF and brain activity in schizophrenia, people with schizophrenia showed no relationship between plasma BDNF and neural activity in the frontal–parietal–striatal network. We found that the relationship between plasma BDNF and parietal cortex activity was significantly different between groups, with a trend towards a group difference in the caudate. Indeed, in people with schizophrenia, as plasma BDNF levels increased, no parallel change in task-related brain activity was detected in the cortical or subcortical regions examined.

Previous studies have also suggested that circulating BDNF may be a biomarker of memory and of general cognitive function in healthy adults, supporting the hypothesis that it could be a surrogate marker of cortical function in humans (Gunstad et al. 2008; Komulainen et al. 2008). Our finding provides the
first biological link between peripheral brain-derived growth factors and brain physiology in healthy humans. However, we did not identify positive correlations between plasma BDNF and prefrontal cortex activity, one of the main regions of interest in our study where task-related activity is high and where BDNF synthesis is high. This was surprising because cortical activity is one of the strongest inducers of BDNF levels in the brain (Gall et al. 1991; Dugich-Djordjevic et al. 1992; Wetmore et al. 1994) and BDNF is thought to act locally to increase synaptic strength. However, BDNF is made in highest abundance in pyramidal neurons in cortical layer VI, which project out of the local cortical area to subcortical and other cortical regions (Koralek et al. 1990; Fabri & Burton, 1991). Furthermore, in vivo studies (Rauskolb et al. 2010) suggest that the major mode of BDNF action is through anterograde supply to target regions, which would be consistent with frontally derived BDNF being more strongly linked to parietal cortex (and possibly caudate) activity, as we find in our present study. Thus, we speculate that increased activity of the DLPFC may have equal or greater impact on areas poised to receive BDNF from the DLPFC rather than within the DLPFC.

The observed relationship between blood BDNF levels and brain activity illustrates the role of blood BDNF in the healthy brain; however, the significantly different correlation between plasma BDNF levels and task-related neural activity in schizophrenia suggests that blood BDNF may not be a suitable biomarker of functional or task-related activity in schizophrenia. There may be different reasons for the absence of a linear relationship between blood BDNF and brain activity in schizophrenia. As cortical activity is one of the strongest inducers of BDNF levels in the brain (Gall et al. 1991; Dugich-Djordjevic et al. 1992; Wetmore et al. 1994) and cortical activity is often reduced in schizophrenia (Berman et al. 1986; Vercammen et al. 2012), then decreased activity in schizophrenia should lead to reduced BDNF levels. Several studies have shown a reduction of BDNF mRNA, protein and BDNF trkB receptor in schizophrenia (Iritani et al. 2003; Weickert et al. 2003; Hashimoto et al. 2005; Wong et al. 2010; Ray et al. 2014). Additionally, compromised axonal transport of BDNF from the cortex may yield less bioavailable BDNF within the striatum in schizophrenia. Thus, significantly reduced cortical BDNF levels in schizophrenia (representing a floor effect) might explain why there was no correlation with neural activity in the ROIs examined.

Conversely, we found that plasma BDNF levels were significantly increased in our cohort of people with schizophrenia.

**Table 4.** Fisher’s r to z transformation comparing correlation strengths of BDNF levels and brain activity between people with schizophrenia and healthy controls

|                      | Left DLPFC | Right DLPFC | Left caudate | Right caudate | Left parietal cortex | Right parietal cortex |
|----------------------|------------|-------------|--------------|---------------|----------------------|-----------------------|
| Z                    | −0.38      | −0.09       | −1.59        | −1.03         | −0.69                | −1.66                 |
| p value              | 0.35       | 0.46        | 0.06         | 0.15          | 0.25                 | 0.05                  |

BDNF, Brain-derived neurotrophic factor; DLPFC, dorsolateral prefrontal cortex.

**Fig. 3.** Correlation between plasma brain-derived neurotrophic factor (BDNF) and brain activity in (a) the left caudate and (b) the right parietal cortex of healthy controls.
schizophrenia compared to healthy adults. This suggests that there may be increased synthesis of BDNF (and availability in circulation) in our patient sample; thus, reduced BDNF may not be the most likely explanation for a loss of frontal–striatal activity in our study. However, it is possible that the BDNF may not be readily available to the neural regions typically activated during probabilistic association learning in schizophrenia leading to an uncoupling of blood BDNF levels and brain activity. In support of this possibility, we have found that the normal function of BDNF may be interrupted due to increased truncated trkB receptors in brains of people with schizophrenia (Wong et al. 2013). Lower levels of the full-length BDNF receptor have also been reported in cortical and hippocampal regions in schizophrenia (Weickert et al. 2005; Thompson Ray et al. 2011; Ray et al. 2014). We suggest that although most people with schizophrenia may synthesize less cortical BDNF, even when BDNF levels are normal or increased, there still may be a block in the function of BDNF through increased presence of truncated trkB receptors within the brains of people with schizophrenia.

Antipsychotics may also contribute to the abnormal relationship between plasma BDNF levels and caudate activity in schizophrenia. In the present study, there was a moderately strong, but non-significant, trend towards a positive relationship between daily antipsychotic dose and plasma BDNF levels, such that as the antipsychotic dose increased, circulating BDNF levels also increased, which supports a recent study showing a positive relationship between BDNF levels and antipsychotic dose (Pedrini et al. 2011). Antipsychotics tend to decrease dopamine binding in the caudate nucleus in schizophrenia (Kegeles et al. 2008), which may result in changes to caudate activity. It is thus possible that antipsychotics may be responsible for both the increased BDNF levels in our cohort of people with schizophrenia and the blunted caudate nucleus activity seen during probabilistic association learning. However, the literature to date in this area is inconsistent and other studies of antipsychotic effects on BDNF levels report that both peripheral (Tan et al. 2005; Grillo et al. 2007; Rizos et al. 2010) and brain BDNF levels (Lipska et al. 2001; Chlan-Fourney et al. 2002) are often down-regulated by antipsychotics.

There are several potential limitations to the present study. It is possible that the lack of a BOLD–BDNF relationship in people with schizophrenia may be due to potential confounds or epiphenomena in a relatively small sample. However, our sample size is consistent with other fMRI studies of people with schizophrenia and, based on the between-groups statistical comparison, we were able to demonstrate a significant difference between groups.

The relationship between plasma BDNF levels and BDNF levels in the brain is not well established in humans; BDNF is expressed at relatively high levels in peripheral tissues, including the lung, heart and bone marrow (Scarisbrick et al. 1993; Yamamoto et al. 1996; Takemura et al. 2012), with T cells being a cellular source of BDNF (Braun et al. 1999). BDNF is also found in tissue that supports sensory nerve innervation (e.g. muscle and skin) and increased BDNF from target tissues can increase innervation from sensory neurons (Ernfors et al. 1994; LeMaster et al. 1999; Hsieh et al. 2013). Thus, it is possible that the source of BDNF in our study is peripheral and is not derived from the CNS. In addition, much of the circulating BDNF is stored in platelets, which is released upon clotting. However, it is less likely that the peripheral BDNF assayed in our study is platelet derived because we assayed plasma samples in which there is no clotting. Thus, we speculate that the plasma BDNF may be derived at least in part from the CNS. Indeed, some evidence has accrued from animal studies to suggest that there is a relationship between blood and brain BDNF levels. These studies have shown a relationship between measures of blood and brain BDNF levels (Karege et al. 2002) that are increased by neural activity and specifically glutamatergic synaptic activity (Goodman et al. 1996; Hartmann et al. 2001). These animal studies have shown that BDNF from peripheral blood can come from the brain and that BDNF does cross the blood–brain barrier (Pan et al. 1998; Sartorius et al. 2009) whereas one study has shown a change in BDNF with age that was not found in platelets (Karege et al. 2002). Thus, there is evidence from animal studies to suggest that the BDNF we measured in peripheral human blood does not necessarily come from the platelets but instead may come from the brain and specifically glutamatergic synapse activity.

Another limitation pertains to the lack of a relationship between plasma BDNF levels and probabilistic association learning performance in either group despite positive correlations with brain activity. One possible explanation may be the restricted range of probabilistic association learning performance in both groups, which has been previously reported in the WPT (Weickert et al. 2002). Lack of a relationship between plasma BDNF levels and probabilistic association learning should not be due to a lack of learning in the groups on the WPT because healthy controls showed performance above chance levels from trial block 2 onwards and patients showed performance above chance levels from trial block 4 onwards.

There was a significant difference in age between the groups, which may influence BDNF levels, brain activity and learning. We obtained a significant relationship between age and BOLD activity only in the right
caudate nucleus in controls. We did not obtain significant group differences in learning even though the groups differed significantly in age. We recruited from a relatively restricted age range (18–50 years) to reduce the effects of age. Correlations between plasma BDNF levels and age showed no strong, significant relationship between BDNF and age in this sample, which may be due to the relatively restricted age range in our sample. Increasing age is generally associated with decreasing BDNF levels (Lommatzsch et al. 2005). Conversely, we obtained an effect that was opposite to what would be predicted, such that patients with schizophrenia (who were significantly older than the controls) displayed significantly higher BDNF levels than controls. Another factor, such as sex, may be responsible for the increased BDNF levels in the patients. We showed that females with schizophrenia displayed increased plasma BDNF levels relative to males with schizophrenia and healthy men and women. At 53% women with schizophrenia, our sample had a higher prevalence of women than most studies of schizophrenia. However, our sample sizes of men and women with schizophrenia were small, and hence this effect would need to be replicated in larger samples. Some studies have shown increased peripheral BDNF levels in females relative to men (Zhang et al. 2012a).

The difference between our findings and the majority of other studies on peripheral BDNF in chronically ill people with schizophrenia may be explained by the fact that our patient sample contained some recent-onset patients. One of the most potent inducers of brain BDNF is cortical glutamate levels and a recent meta-analysis suggests that cortical glutamate levels may be higher in the early phase of illness (Marsman et al. 2013). As our patient sample included some individuals who were within the first 5 years of diagnosis, they may have been at a higher glutamate state overall, relative to a more chronically ill sample when cortical glutamate has been consistently shown to be decreased (Marsman et al. 2013). Furthermore, many of the people with schizophrenia in our study had a diagnosis of schizoaffective disorder and were receiving clozapine and/or antidepressants, which may increase BDNF levels (Pedrini et al. 2011; Thompson Ray et al. 2011; Kim et al. 2012; Martocchia et al. 2014; Mitic et al. 2014; Ray et al. 2014).

We did not exclude smokers in our sample. In our study, the effects of nicotine were not controlled. As is often the case in comparisons of people with schizophrenia to control groups, there was a higher prevalence of smokers in the patient group. There would have been no nicotine withdrawal effects because smokers were allowed to smoke ad libitum. A recent study (Paelecke-Habermann et al. 2013) has also shown no significant difference in probabilistic association learning between satiated and abstinent smokers; however, there was a significant difference in probabilistic association learning between non-smokers and both casual and chronic smokers, in which the smokers displayed impaired learning. Although the prevalence of smokers was greater in the people with schizophrenia in our study, there were no significant differences in learning between the patients and healthy controls.

In summary, the findings from the present study show the first positive relationship between plasma BDNF levels and parietal cortex (and possibly caudate) activity in healthy adults during probabilistic association learning, but no relationship between plasma BDNF levels and brain activity in schizophrenia. These findings suggest that plasma BDNF levels may reflect cortical BDNF signaling during learning in healthy adults. Conversely, in schizophrenia, peripheral BDNF levels do not relate to prefrontal–parietal cortex and caudate nucleus activity, providing further evidence of abnormal BDNF trophic activity and blunted frontal–parietal–striatal function (Pantelis et al. 1997; Meyer-Lindenberg et al. 2002; Weickert et al. 2009). Future studies to determine the mechanism of the abnormal BDNF and brain activity relationship in schizophrenia would provide further insight into the role of trophic factors in schizophrenia. This preliminary study is the first to describe a relationship between plasma BDNF levels and neural activity during learning in healthy adults, which is disrupted in schizophrenia.

Supplementary material

For supplementary material accompanying this paper visit http://dx.doi.org/10.1017/S0033291714001925.

Acknowledgments

This work was supported by the University of New South Wales School of Psychiatry; National Health and Medical Research Council Project Grant no. 568807; Neuroscience Research Australia; the Schizophrenia Research Institute (using funding from the NSW Ministry of Health and the Macquarie Group Foundation); and the Australian Schizophrenia Research Bank, which is supported by the National Health and Medical Research Council of Australia; the Pratt Foundation; Ramsay Health Care; and the Viertal Charitable Foundation. C.S.W. is a recipient of a National Health and Medical Research Council (Australia) Senior Research Fellowship (no. 1021970). A.J.S. is a recipient of the Ian Scott Scholarship awarded by Australian Rotary Health. We thank
L. Moore, N. Vella and A. Rothwell for assistance with recruitment and administration and scoring of neuropsychological and symptom assessments.

Declaration of Interest
None.

References

Alexander GE, DeLong MR, Strick PL (1986). Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annual Review of Neuroscience 9, 357–381.

Altar CA, Cai N, Bliven T, Juhasz M, Conner JM, Acheson AL, Lindsay RM, Wiegand SJ (1997). Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 389, 856–860.

Altar CA, DiStefano PS (1998). Neurotrophin trafficking by anterograde transport. Trends in Neurosciences 21, 433–437.

Berman KF, Zec RF, Weinberger DR (1986). Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. II. Role of neuroleptic treatment, attention, and mental effort. Archives of General Psychiatry 43, 126–135.

Braun A, Lommatzsch M, Mannsfeld A, Neuhaus-Steinmetz U, Fischer A, Schnoy N, Lewin GR, Renz H (1999). Cellular sources of enhanced brain-derived neurotrophic factor production in a mouse model of allergic inflammation. American Journal of Respiratory Cell and Molecular Biology 21, 537–546.

Buckley PF, Pillai A, Evans D, Stirewalt E, Mahadik S (2007). Brain derived neurotrophic factor in first-episode psychosis. Schizophrenia Research 91, 1–5.

Chlan-Fourney J, Ashe P, Nylen K, Juorio AV, Li XM (2002). Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration. Brain Research 954, 11–20.

Dempster E, Toulopoulou T, McDonald C, Bramon E, Walshe M, Filbey F, Wickham H, Sham PC, Murray RM, Collier DA (2005). Association between BDNF val66met genotype and episodic memory. Brain Research 1028, 73–75.

Dieni S, Matsumoto T, Dekkers M, Rauskolb S, Ionescu MS, Deogracias R, Gundelfinger ED, Kojima M, Nestel S, Frotscher M, Barde YA (2012). BDNF and its pro-peptide are stored in presynaptic dense core vesicles in brain neurons. Journal of Cell Biology 196, 775–788.

Dugich-Djordjevic MM, Tocco G, Lapchak PA, Pasinetti GM, Najm I, Baudry M, Hefi F (1992). Regionally specific and rapid increases in brain-derived neurotrophic factor messenger RNA in the adult rat brain following seizures induced by systemic administration of kainic acid. Neuroscience 47, 303–315.

Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, Zaitsev E, Gold B, Goldman D, Dean M, Lu B, Weinberger DR (2003). The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112, 257–269.

Elmfors P, Lee KF, Jaenisch R (1994). Mice lacking brain-derived neurotrophic factor develop with sensory deficits. Nature 368, 147–150.

Fabri M, Burton H (1991). Ipsilateral cortical connections of primary somatic sensory cortex in rats. Journal of Comparative Neurology 311, 405–424.

Fera F, Weickert TW, Goldberg TE, Tessitore A, Hariri A, Das S, Lee S, Zoltick B, Meeter M, Myers CE, Gluck MA, Weinberger DR, Mattay VS (2005). Neural mechanisms underlying probabilistic category learning in normal aging. Journal of Neuroscience 25, 11340–11348.

First MB, Spitzer RL, Gibbion M, Williams JB (2002). Structured Clinical Interview for DSM-IV-TR Axis I Disorders – Patient Edition (SCID-I/P). Biometric Research Department, New York State Psychiatric Institute: New York, NY.

Foerde K, Poldrack RA, Khan BJ, Sabb FW, Bookheimer SY, Bilder RM, Guthrie D, Granholm E, Nuechterlein KH, Marder SR, Asarnow RF (2008). Selective corticostriatal dysfunction in schizophrenia: examination of motor and cognitive skill learning. Neuropsychology 22, 100–109.

Galli C, Lauterborn J, Bundman M, Murray K, Isackson P (1991). Seizures and the regulation of neurotrophic factor and neuropeptide gene expression in brain. Epilepsy Research 4, 225–245.

Gama CS, Andreazza AC, Kunz M, Berk M, Belmonte-de-Abreu PS, Kapczinski F (2007). Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neuroscience Letters 420, 45–48.

Goodman LJ, Valverde J, Lim F, Geschwind MD, Federoff HJ, Geller Al, Hefti F (1996). Regulated release and polarized localization of brain-derived neurotrophic factor in hippocampal neurons. Molecular and Cellular Neurosciences 7, 222–238.

Green MJ, Matheson SL, Shepherd A, Weickert CS, Carr VJ (2011). Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Molecular Psychiatry 16, 960–972.

Grillo RW, Ottoni GL, Leke R, Souza DO, Portela LV, Lara DR (2007). Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. Journal of Psychiatric Research 41, 31–35.

Gunstad J, Benitez A, Smith J, Glickman E, Spitznagel MB, Alexander T, Juvancic-Heltzel J, Murray L (2008). Serum brain-derived neurotrophic factor is associated with cognitive function in healthy older adults. Journal of Geriatric Psychiatry and Neurology 21, 166–170.

Hariri AR, Goldberg TE, Mattay VS, Kolachana BS, Callicott JH, Egan MF, Weinberger DR (2003). Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. Journal of Neuroscience 23, 6690–6694.

Hartmann M, Heumann R, Lessmann V (2001). Synaptic secretion of BDNF after high-frequency stimulation of glutamatergic synapses. EMBO Journal 20, 5887–5897.
Hashimoto T, Bergen SE, Nguyen QL, Xu B, Monteggia LM, Pierri JN, Sun Z, Sampson AR, Lewis DA (2005). Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. *Journal of Neuroscience* 25, 372–383.

Hofer M, Pagliusi SR, Hohn A, Leibrock J, Barde YA (1990). Regional distribution of brain-derived neurotrophic factor mRNA in the adult mouse brain. *EMBO Journal* 9, 2459–2464.

Horan WP, Green MF, Knowlton BJ, Wynn JK, Mintz J, Nuechterlein KH (2008). Impaired implicit learning in schizophrenia. *Neuropsychology* 22, 606–617.

Howes OD, Montgomery AJ, Asselin MC, Murray RM, Valli I, Tabraham P, Bramon-Bosch E, Valmaggia L, Johns L, Broome M, McGuire PK, Grasby PM (2009). Elevated striatal dopamine function linked to prodromal signs of schizophrenia. *Archives of General Psychiatry* 66, 13–20.

Hsieh JH, Lin WM, Chang LY, Wu CT, Pu CM, Wu JT, Hsieh ST (2013). Patterns of target tissue innervation and trophic factor expression after nerve grafting. *Plastic and Reconstructive Surgery* 131, 989–1000.

Iritani S, Niizato K, Nawa H, Ikeda K, Emson PC (2003). Immunohistochemical study of brain-derived neurotrophic factor and its receptor, TrkB, in the hippocampal formation of schizophrenic brains. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 27, 801–807.

Karege F, Schwald M, Cisse M (2002). Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. *Neuroscience Letters* 328, 261–264.

Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophrenia Bulletin* 13, 261–276.

Kegeles LS, Slifstein M, Franklin WG, Xu X, Hackett E, Bae SA, Gonzales R, Kim JH, Alvarez B, Gil R, Laruelle M, Abi-Dargham A (2008). Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride. *Neuroscience* 152, 3111–3125.

Kim HW, Cheon Y, Modi HR, Rapoport SI, Rao JS (2012). Effects of chronic clozapine administration on markers of striatal dopaminergic function in schizophrenia. *Neurobiology of Aging* 33, 2641–2649.

Komalainen P, Pedersen M, Hanninen T, Bruunsgaard H, Lakka TA, Kivipelto M, Hassenin M, Rauramaa TH, Pedersen BK, Rauramaa R (2008). BDNF is a novel marker of cognitive function in ageing women: the DR EXTRA Study. *Neurobiology of Learning and Memory* 90, 596–603.

Koralek KA, Olavarria J, Killackey HP (1990). Areal and laminar organization of corticocortical projections in the rat somatosensory cortex. *Journal of Comparative Neurology* 299, 133–150.

Lee BH, Kim YK (2009). Increased plasma brain-derived neurotropic factor, not nerve growth factor-Beta, in schizophrenia patients with better response to risperidone treatment. *Neuropsychobiology* 59, 51–58.

LeMaster AM, Krimm RF, Davis BM, Noel T, Forbes ME, Johnson JE, Albers KM (1999). Overexpression of brain-derived neurotrophic factor enhances sensory innervation and selectively increases neuron number. *Journal of Neuroscience* 19, 5919–5931.

Leucht S, Wahlbeck K, Hamann J, Kissling W (2003). New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. *Lancet* 361, 1581–1589.

Lipska BK, Khaing ZZ, Weickert CS, Weinberger DR (2001). BDNF mRNA expression in rat hippocampus and prefrontal cortex: effects of neonatal ventral hippocampal damage and antipsychotic drugs. *European Journal of Neuroscience* 15, 134–144.

Lommatzsch M, Zingler D, Schuhbaeck K, Schloetcke K, Zingler C, Schuff-Werner P, Virchow JC (2005). The impact of age, weight and gender on BDNF levels in human platelets and plasma. *Neurobiology of Aging* 26, 115–123.

Lu B (2003). BDNF and activity-dependent synaptic modulation. *Learning and Memory* 10, 86–98.

Lu B, Chow A (1999). Neurotrophins and hippocampal synaptic transmission and plasticity. *Journal of Neuroscience Research* 58, 76–87.

Marsman A, van den Heuvel MP, Klomp DW, Kohn RS, Luijtjen PR, Hulshoff Pol HE (2013). Glutamate in schizophrenia: a focused review and meta-analysis of (1) H-MRS studies. *Schizophrenia Bulletin* 39, 120–129.

Martocchia A, Curto M, Scaccianoce S, Comite F, Xenos D, Nasca C, Falaschi GM, Ferracuti S, Girardi P, Nicoletti F, Falaschi P (2014). Effects of escitalopram on serum BDNF levels in elderly patients with depression: a preliminary report. *Aging Clinical and Experimental Research* 26, 461–464.

Meyer-Lindenberg A, Miletich RS, Kohn PD, Esposito G, Carson RE, Quarantelli M, Weinberger DR, Berman KF (2002). Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. *Nature Neuroscience* 5, 267–271.

Mitic M, Lukic I, Bozovic N, Djordjevic J, Adzic M (2014). Fluoxetine signature on hippocampal MAPK signalling in sex-dependent manner. *Journal of Molecular Neuroscience*. Published online: 21 May 2014. doi:10.1007/S12031-014-0328-1.

Morris RW, Vercammen A, Lenroot R, Moore L, Langton JM, Short B, Kulkarni J, Curtis J, O’Donnell M, Weickert CS, Weickert TW (2012). Disambiguating ventral striatum fMRI-related blood signal during reward prediction in schizophrenia. *Molecular Psychiatry* 17, 280–289.

Murray GK, Corlett PR, Clark L, Pessiglione M, Blackwell AD, Honey G, Jones PB, Bullmore ET, Robbins TW, Fletcher PC (2008). Substantia nigra/ventral tegmental reward prediction error disruption in psychosis. *Molecular Psychiatry* 13, 239, 267–276.

Paelcke-Habermann Y, Paelcke M, Giegerich K, Reschke K, Kubler A (2013). Implicit and explicit reward learning in chronic nicotine use. *Drug and Alcohol Dependence* 129, 8–17.

Palmer BW, Dawes SE, Heaton RK (2009). What do we know about neuropsychological aspects of schizophrenia? *Neuropsychology Review* 19, 365–384.
Pantelis C, Barnes TR, Nelson HE, Tanner S, Weatherley L, Owen AM, Robbins TW (1997). Frontal-striatal cognitive deficits in patients with chronic schizophrenia. *Brain* 120 (Pt 10), 1823–1843.

Pedrini M, Chendo I, Grande I, Lobato MI, Belmonte-de-Abreu PS, Lersch C, Walz J, Kauer-Sant’anna M, Kapczinski F, Gama CS (2011). Serum brain-derived neurotrophic factor and clozapine daily dose in patients with schizophrenia: a positive correlation. *Neuroscience Letters* 491, 207–210.

Pirildar S, Gonul AS, Taneli F, Akdeniz F (2004). Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 28, 709–713.

Poldrack RA, Prabhakaran V, Seger CA, Gabrieli JD (2014). Impaired automatization of a cognitive skill. *Cerebral Cortex* 24, 32–42.

Polderk RA, Prabhakaran V, Seger CA, Gabrieli JD (1999). Striatal activation during acquisition of a cognitive skill. *Neuropsychology* 13, 564–574.

Poo MM (2001). Neurotrophins as synaptic modulators. *Nature Reviews Neuroscience* 2, 24–32.

Rauskolb S, Zagrebelsky M, Dreznjak A, Deogracias R, Matsumoto T, Wiese S, Erne B, Sendtner M, Schaeren-Wiemers N, Korte M, Barde YA (2010). Global deprivation of brain-derived neurotrophic factor in the CNS reveals an area-specific requirement for dendritic growth. *Journal of Neuroscience* 30, 1739–1749.

Ray MT, Shannon Weickert C, Webster MJ (2014). Decreased BDNF and TrkB mRNA expression in multiple cortical areas of patients with schizophrenia and mood disorders. *Translational Psychiatry* 4, e389.

Reis HJ, Nicolato R, Barbosa IG, Teixeira do Prado PH, Romano-Silva MA, Teixeira AL (2008). Increased serum levels of brain-derived neurotrophic factor in chronic institutionalized patients with schizophrenia. *Neuroscience Letters* 439, 157–159.

Rizos EN, Papadopouloou A, Laskos E, Michalopouloou PG, Kastania A, Vasilopoulos D, Katsafouros K, Lykouras L (2010). Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics. *World Journal of Biological Psychiatry* 11, 251–255.

Rizos EN, Rontos I, Laskos E, Arsenis G, Michalopouloou PG, Vasilopoulos D, Gournelis R, Lykouras L (2008). Investigation of serum BDNF levels in drug-naive patients with schizophrenia. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 32, 1308–1311.

Sartorius A, Hellweg R, Litzke J, Vogt M, Dormann C, Vollmayr B, Danker-Hopfe H, Gass P (2009). Correlations and discrepancies between serum and brain tissue levels of neurotrophins after electroconvulsive treatment in rats. *Pharmacopsychiatry* 42, 270–276.

Scarisbrick IA, Jones EG, Isackson PJ (1993). Coexpression of mRNAs for NGF, BDNF, and NT-3 in the cardiovascular system of the pre- and postnatal rat. *Journal of Neuroscience* 13, 875–893.

Schmidt HD, Duman RS (2010). Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models. *Neuropsychopharmacology* 35, 2378–2391.

Takemura Y, Imai S, Kojima H, Katagi M, Yamakawa I, Kasahara T, Urabe H, Terashima T, Yasuda H, Chan L, Kimura H, Matsuuse Y (2012). Brain-derived neurotrophic factor from bone marrow-dressed cells promotes post-injury repair of peripheral nerve. PLoS ONE 7, e44592.

TanYL, Zhou DF, Cao LY, Zou YZ, Zhang XY (2005). Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics. *Neuroscience Letters* 382, 27–32.

Thompson Ray M, Weickert CS, Wyatt E, Webster MJ (2011). Decreased BDNF, trkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders. *Journal of Psychiatry and Neuroscience* 36, 195–203.

Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, Mazoyer B, Joliot M (2002). Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. *NeuroImage* 15, 273–289.

Vercammen A, Morris R, Green MJ, Lenroot R, Kulkarni J, Carr VJ, Weickert CS, Weickert TW (2012). Reduced neural activity of the prefrontal cognitive control circuitry during response inhibition to negative words in people with schizophrenia. *Journal of Psychiatry and Neuroscience* 37, 379–388.

Wagshal D, Knowlton BJ, Cohen JR, Poldrack RA, Bookheimer SY, Bilder RM, Asarnow RF (2014). Impaired automatization of a cognitive skill in first-degree relatives of patients with schizophrenia. *Psychiatry Research* 215, 294–299.

Wagshal D, Knowlton BJ, Cohen JR, Poldrack RA, Bookheimer SY, Bilder RM, Fernandez VG, Asarnow RF (2012). Deficits in probabilistic classification learning and liability for schizophrenia. *Psychiatry Research* 200, 167–172.

Wagshal D, Knowlton BJ, Suthana NA, Cohen JR, Poldrack RA, Bookheimer SY, Bilder RM, Asarnow RF (2013). Evidence for corticostriatal dysfunction during cognitive skill learning in adolescent siblings of patients with childhood-onset schizophrenia. *Schizophrenia Bulletin*. Published online: 25 October 2013. doi:10.1093/schbul/sbt147.

Wechsler D (1997). *Wechsler Adult Intelligence Scale*. The Psychological Corporation: San Antonio, TX.

Wechsler D (2001). *Wechsler Test of Adult Reading*. The Psychological Corporation: San Antonio, TX.

Weickert CS, Hyde TM, Lipska BK, Herman MM, Weinberger DR, Kleinman JE (2003). Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. *Molecular Psychiatry* 8, 592–610.

Weickert CS, Ligons DL, Romanczyk T, Ungaro G, Hyde TM, Herman MM, Weinberger DR, Kleinman JE (2005). Reductions in neurotrophin receptor mRNAs in the prefrontal cortex of patients with schizophrenia. *Molecular Psychiatry* 10, 637–650.
Weickert TW, Goldberg TE, Callicott JH, Chen Q, Apud JA, Das S, Zollick BJ, Egan MF, Meeter M, Myers C, Gluck MA, Weinberger DR, Mattay VS (2009). Neural correlates of probabilistic category learning in patients with schizophrenia. Journal of Neuroscience 29, 1244–1254.

Weickert TW, Goldberg TE, Egan MF, Apud JA, Meeter M, Myers CE, Gluck MA, Weinberger DR (2010). Relative risk of probabilistic category learning deficits in patients with schizophrenia and their siblings. Biological Psychiatry 67, 948–955.

Weickert TW, Goldberg TE, Gold JM, Bigelow LB, Egan MF, Weinberger DR (2000). Cognitive impairments in patients with schizophrenia displaying preserved and compromised intellect. Archives of General Psychiatry 57, 907–913.

Weickert TW, Terrazas A, Bigelow LB, Malley JD, Hyde T, Egan MF, Weinberger DR, Goldberg TE (2002). Habit and skill learning in schizophrenia: evidence of normal striatal processing with abnormal cortical input. Learning and Memory 9, 430–442.

Wetmore C, Olson L, Bean AJ (1994). Regulation of brain-derived neurotrophic factor (BDNF) expression and release from hippocampal neurons is mediated by non-NMDA type glutamate receptors. Journal of Neuroscience 14, 1688–1700.

Wong J, Hyde TM, Cassano HL, Deep-Soboslay A, Kleinman JE, Weickert CS (2010). Promoter specific alterations of brain-derived neurotrophic factor mRNA in schizophrenia. Neuroscience 169, 1071–1084.

Wong J, Rothmond DA, Webster MJ, Weickert CS (2013). Increases in two truncated TrkB isoforms in the prefrontal cortex of people with schizophrenia. Schizophrenia Bulletin 39, 130–140.

Woods SW (2003). Chlorpromazine equivalent doses for the newer atypical antipsychotics. Journal of Clinical Psychiatry 64, 663–667.

Xiu MH, Hui L, Dang YF, Hou TD, Zhang CX, Zheng YL, Chen da C, Kosten TR, Zhang XY (2009). Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics. Progress in Neuro-Psychopharmacology and Biological Psychiatry 33, 1508–1512.

Yamamoto M, Sobue G, Yamamoto K, Terao S, Mitsuma T (1996). Expression of mRNAs for neurotrophic factors (NGF, BDNF, NT-3, and GDNF) and their receptors (p75NGFR, trkA, trkB, and trkC) in the adult human peripheral nervous system and nonneural tissues. Neurochemical Research 21, 929–938.

Yu H, Zhang Z, Shi Y, Bai F, Xie C, Qian Y, Yuan Y, Deng L (2008). Association study of the decreased serum BDNF concentrations in amnestic mild cognitive impairment and the Val66Met polymorphism in Chinese Han. Journal of Clinical Psychiatry 69, 1104–1111.

Zhang XY, Chen da C, Xiu MH, Haile CN, Luo X, Xu K, Zhang HP, Zuo L, Zhang Z, Zhang X, Kosten TA, Kosten TR (2012a). Cognitive and serum BDNF correlates of BDNF Val66Met gene polymorphism in patients with schizophrenia and normal controls. Human Genetics 131, 1187–1195.

Zhang XY, Liang J, Chen da C, Xiu MH, Yang FD, Kosten TA, Kosten TR (2012b). Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia. Psychopharmacology 222, 277–284.